Oncology in Clinical Practice最新文献

{"title":"A case of a patient with embryonal sarcoma presenting with abdominal pain","authors":"Mohsen Reza Mansoorian, Shahriar Sabouri","doi":"10.5603/ocp.95596","DOIUrl":"https://doi.org/10.5603/ocp.95596","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139201006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Between “opioidophobia” and the opioid crisis: a cross-sectional comparison of opinions on opioid analgesic treatment between palliative care patients with cancer and physicians in Poland","authors":"Maria Wysocka, A. Kieszkowska-Grudny, J. Klimkiewicz, Jerzy Jarosz, Martyna Hordowicz, Andrzej Silczuk, Tomasz Pasierski, A. Klimkiewicz","doi":"10.5603/ocp.96515","DOIUrl":"https://doi.org/10.5603/ocp.96515","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139241135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two-center experience comparing the use of the FLOT4 and CROSS schemes for patients with gastric, esophageal, and gastroesophageal junction adenocarcinoma","authors":"Irene Solana López, D. Gutiérrez Abad, M. V. de Torres Olombrada, Elia Martínez Moreno, I. Juez Martel, Alicia Hurtado Nuño, Ana Manuela Martín Fernández de Soignie, C. De Zea Luque, Nadia Sánchez Baños, Fátima Escalona Martín, Beatriz Losada Vila, Carmen Pantín González, L. Rodríguez Lajusticia, Diego Malón Giménez, B. Jiménez Munarriz, Roberto Hernández López, J. Calzas Rodríguez, Juan Antonio Guerra Martínez","doi":"10.5603/ocp.97428","DOIUrl":"https://doi.org/10.5603/ocp.97428","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139276568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of different concentrations of anti-PD-1 and anti-PD-L1 antibodies on the activity of immune system cells in patients with non-small cell lung cancer","authors":"A. Bożyk, K. Wojas-Krawczyk, M. Nicoś, P. Krawczyk","doi":"10.5603/ocp.96792","DOIUrl":"https://doi.org/10.5603/ocp.96792","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.5,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139288137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trastuzumab deruxtecan in the treatment of adult patients with HER2-positive breast cancer","authors":"Joanna Kufel-Grabowska","doi":"10.5603/ocp.97612","DOIUrl":"https://doi.org/10.5603/ocp.97612","url":null,"abstract":"In 2020, approximately 18,000 women in Poland were diagnosed with breast cancer, and 6,000 of them died. In recent years, we have witnessed significant progress in the diagnosis and treatment of breast cancer patients. When detected early and treated appropriately, the prognosis is very good, and even some patients with distant metastases have experienced long-term survival. The most common biological subtype is hormone receptor-positive breast cancer, accounting for about 70% of diagnoses, showing expression of estrogen and progesterone receptors. Triple-negative breast cancer and HER2-positive breast cancer each make up approximately 15% of all cases. In the treatment of advanced HER2-positive breast cancer, a combination of docetaxel with pertuzumab and trastuzumab is used in the first line. In subsequent lines of treatment, options include trastuzumab deruxtecan (T-DXd), trastuzumab emtansine, lapatinib, tucatinib, margetuximab, and trastuzumab. Trastuzumab derukstekan is an immunoconjugate that, upon entering the cell, releases a cytostatic agent that destroys its genetic material and neighboring cells (the “bystander effect”). It significantly prolongs the time to disease progression and overall survival compared to standard treatments used in the second and subsequent lines of treatment. It represents an effective and valuable therapeutic option for patients with early-stage HER2- positive metastatic breast cancer.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136233914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immunochemotherapy in a 25-year-old male patient with small-cell lung cancer","authors":"Aleksandra Łomża, Bernadeta Maliszewska, Łukasz Łaba, Izabela Chmielewska, Iwona Paśnik, Renata Langfort, Michał Gil, Krawczyk Paweł","doi":"10.5603/ocp.97487","DOIUrl":"https://doi.org/10.5603/ocp.97487","url":null,"abstract":"Lung cancer is the leading cause of cancer-related deaths, both in males and females. Small-cell lung cancer (SCLC) is a strongly tobacco-dependent type of lung cancer characterized by aggressiveness, rapid growth, and a high tendency to metastasize. SCLC is the most commonly diagnosed in an advanced — metastatic — stage in patients with many comorbidities and inadequate performance status. However, based on the most current recommendations, chemotherapy in combination with immunotherapy at the extensive stage (ES) of SCLC, significantly improves the therapeutic efficiency. Here, we present a case of a 25-year-old man, diagnosed with SCLC, with a medical history of 10 years of smoking e-cigarettes and marijuana as well as the use of amphetamine and alcohol. In the diagnosis process, considering the young age of the patient, the next-generation sequencing (NGS) was performed, but no molecular alterations in oncogenes were found. During the immunochemotherapy with atezolizumab, carboplatin, and etoposide, immune-related adverse events (irAEs), in the form of hepatotoxicity, were observed. After the toxicity subsided, the immunotherapy was continued with a very good effect and tolerance. The patient has remained in partial remission for 9 months. The presented case highlights the possibility of treatment continuation despite mild adverse events triggered by immunotherapy and the need for more research in the group of young patients diagnosed with SCLC.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136262156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on Trastuzumab deruxtecan in the treatment of adult patients with HER-positive breast cancer","authors":"Maciej Krzakowski","doi":"10.5603/ocp.97613","DOIUrl":"https://doi.org/10.5603/ocp.97613","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136233915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Systemic treatment of patients with advanced pancreatic cancer — is there still a place for gemcitabine in the first-line setting? Experience of Polish oncology centers","authors":"Ireneusz Raczyński, Patryk Zając, Joanna Streb, Bogumiła Czartoryska-Arłukowicz, Aleksandra Chruściana-Bołtuć, Małgorzata Talerczyk, Katarzyna Wierzbicka, Agnieszka Siedlaczek, Weronika Radecka, Michał Jurczyk, Barbara Radecka","doi":"10.5603/ocp.97305","DOIUrl":"https://doi.org/10.5603/ocp.97305","url":null,"abstract":"Introduction. Despite some progress in the treatment of patients with pancreatic cancer, it is still a malignancy with a poor prognosis, which results from its rapid local growth with a tendency to infiltrate surrounding tissues and metastasize, and late diagnosis at the advanced stage. The use of multi-drug regimens and modern targeted therapies did not completely eliminate the use of gemcitabine in monotherapy, which is a therapeutic option mainly in patients with poor performance status, ineligible for more advanced therapies. This study aimed to evaluate the results of treatment with single-agent gemcitabine in everyday clinical practice in Poland and to attempt to identify the predictors of obtaining long-term responses resulting from this treatment. Material and methods. A retrospective analysis of 167 patients with advanced pancreatic cancer treated with single-agent gemcitabine in five oncology centers in Poland in the years 2017–2022 was conducted. Gemcitabine was used as monotherapy at an initial dose of 1000 mg/m2 of body surface area (BSA) weekly, 7 times in an 8-week cycle, then 3 times in a 4-week cycle. Results. Median overall survival (OS) in the entire group of patients was 6.1 months (range — 0.2–32.3 months), and median progression-free survival (PFS) was 4.2 months (range — 0.2–31.3 months). A group of 60 patients was identified as “long responders” (LR), with a response of at least 6 months and a group of 107 as “short responders” (SR). Median PFS in the LR group was 9.15 months (range — 6.0–31.3 months) and in the SR group, it was 3.2 months (range — 0.2–5.8 months). Median OS was 11.6 months (range — 5.9–30.8) and 3.8 months (range — 0.2–32.3 months), respectively. In multivariate analysis, the likelihood of achieving at least a 6-month response (LR) was assessed using a logistic regression model. The model takes into account four variables: the neutrophil/lymphocyte (NLR) ratio, liver metastases, sex, and Hb level. Conclusions. The obtained results confirm that gemcitabine monotherapy is still useful in the first-line treatment of patients with advanced and metastatic pancreatic adenocarcinoma. An appropriate selection of patients for this treatment may improve the results while maintaining lower toxicity compared to combined treatment.","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135168062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The relationship between inflammation markers, positron emission tomography/ /computed tomography parameters and disease prognosis in advanced non-small-cell lung cancer patients","authors":"Esra Pirinççi, Zeynep Oruç, Senar Ebinç, Yunus Güzel, Halil Kömek, Mehmet Küçüköner, Zuhat Urakçı, Muhammet Ali Kaplan, Bekir Taşdemir, Abdurrahman Işıkdoğan","doi":"10.5603/ocp.97451","DOIUrl":"https://doi.org/10.5603/ocp.97451","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135168355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tracheal cancers","authors":"Aleksandra Piórek, Adam Płużański, Kinga Winiarczyk, Sylwia Tabor, Magdalena Knetki-Wróblewska, Dariusz M. Kowalski, Maciej Krzakowski","doi":"10.5603/ocp.97601","DOIUrl":"https://doi.org/10.5603/ocp.97601","url":null,"abstract":"","PeriodicalId":42942,"journal":{"name":"Oncology in Clinical Practice","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135169208","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}